Non muscle invasive bladder cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The risk of recurrence and progression to muscle-invasive disease varies greatly from person to person with non-muscle invasive bladder cancer (NMIBC), a heterogeneous subclassification of urothelial carcinoma. Each year, approximately 275,000 people are diagnosed with bladder cancer worldwide, and 108,000 people pass away from the condition. 90% of bladder cancers in developed nations are TCC. Nowadays, the majority of NMIBC patients receive treatment through transurethral resection of bladder tumor therapy, or TURBT. This procedure eliminates all visible cancer and can provide additional information regarding the extent of the disease.

Description

A heterogeneous subclassification of urothelial carcinoma called non-muscle invasive bladder cancer (NMIBC) varies greatly from person to person in terms of the likelihood of recurrence and progression to muscle-invasive disease. However, not all patients may be correctly categorized by risk stratification in accordance with American Urological Association (AUA) and European Association of Urology (EAU) standards or by using nomograms/risk calculators developed from clinical trial data. A vital strategy for balancing disease management with potential side effects is to include intravenous medications in risk-adapted adjuvant treatment regimens. When different chemotherapeutic medications are combined with bacillus Calmette-Guerin (BCG) as an adjuvant intravesical instillation, it is well known and associated with excellent outcomes for the majority of patients. However, 10% or so of patients developed muscle-invasive bladder cancer, and up to 40% of patients experienced a recurrence within 2 years. There is an increasing need for cutting-edge techniques and drugs that are intended to make treating NMIBC less challenging.

Non muscle invasive bladder cancer (Epidemiology)

Every year, approximately 275,000 cases of bladder cancer are discovered worldwide, and 108,000 people pass away from the condition. 90% of bladder cancers in industrialized nations are TCC. The majority of bladder cancers are squamous cell carcinomas in developing nations, particularly in the Middle East and Africa, and the majority of these cancers are caused by schistosome infection. In China, urothelial carcinoma is thought to be the most prevalent type of urinary tract cancer. In endemic schistosomiasis regions of Africa, particularly in Sudan and Egypt, where CSC accounts for two-thirds to three-quarters of all bladder malignancies, SCC is most prevalent. Recent studies from Egypt have demonstrated that this trend has reversed as a result of improved schistosomiasis control in the region, whereas this situation has remained the same in other regions of Africa. Egypt's shift to TCC, which has a stronger association with smoking, is thought to be influenced by rising smoking rates.

Non muscle invasive bladder cancer-Current Market Size & Forecast Trends

The market for non-muscle invasive bladder cancer (NMIBC) is projected to grow significantly, with estimates indicating a value of approximately USD 2.6 billion in 2023 and a compound annual growth rate (CAGR) of 15% expected through 2034. This growth is primarily driven by an increase in NMIBC cases, which are nearing 1.5 million in the seven major markets, particularly among intermediate-risk patients. High-risk NMIBC is anticipated to account for the largest share, estimated at around USD 1.6 billion. Current treatment options include surgery, intravesical immunotherapy (such as BCG), and chemotherapy, with regular monitoring recommended for patients. The market is also supported by recent FDA approvals for key drugs targeting NMIBC, making it well-positioned for substantial growth through 2035 as awareness and treatment options continue to expand.

The most popular form of treatment for the majority of NMIBC patients is transurethral resection of bladder tumor therapy, or TURBT. All of the cancer that is immediately visible is removed during this procedure, which can also provide additional information about the extent of the disease. Additional analysis of the samples is another option that can be used to glean more information about cancer. Some patients need a second TURBT after their first one. This might be suggested, for example, for people with higher grade tumors. TURBT is frequently combined with intravenous therapy. Intravenous therapy may reduce the risk of cancer coming back. Mitomycin C (MMC) is a possible intravesical treatment option. The type of chemotherapy that is typically used in this situation is. For intermediate- and high-risk NMIBC, medical professionals frequently suggest intravenous BCG (Bacillus Calmette-Guerin) therapy. A similar germ to the one that causes tuberculosis is used to create this type of immunotherapy. BCG stimulates the immune system, which prompts these cells to attack the cancerous cells. For those who have NMIBC, a follow-up cystoscopy is also necessary to make sure the cancer hasn't come back. Unfortunately, in patients with NMIBC who have received treatment, cancer frequently returns. It frequently returns to the same stage of cancer six months to a year later. Cystectomy is usually required in these situations when cancer has invaded the muscle wall or has spread more widely throughout the body. Ten to fifteen% of people with NMIBC go on to develop this kind of cancer. Usually, these patients need additional treatments, such as chemotherapy and immunotherapy. In men, a cystectomy usually involves the complete removal of the prostate, seminal vesicles, and bladder. Female patients usually need to have their bladder, uterus, ovaries, and a portion of their vagina removed. The surgeon creates a new route for urine to leave the body during the procedure, a process known as urinary diversion.

Report Highlights

Non muscle invasive bladder cancer- Current Market Trends

Non muscle invasive bladder cancer- Current & Forecasted Cases across the G8 Countries

Non muscle invasive bladder cancer- Market Opportunities and Sales Potential for Agents

Non muscle invasive bladder cancer- Patient-based Market Forecast to 2035

Non muscle invasive bladder cancer- Untapped Business Opportunities

Non muscle invasive bladder cancer- Product Positioning Vis-a-vis Competitors' Products

Non muscle invasive bladder cancer- KOLs Insight